These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis]. Liu Y; Chen Y; Zeng Z; Liu A Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189 [TBL] [Abstract][Full Text] [Related]
4. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474 [TBL] [Abstract][Full Text] [Related]
5. How can we manage the cardiac toxicity of immune checkpoint inhibitors? Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484 [No Abstract] [Full Text] [Related]
6. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918 [TBL] [Abstract][Full Text] [Related]
7. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors. Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879 [TBL] [Abstract][Full Text] [Related]
8. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies. Turker I; Johnson DB Expert Opin Drug Saf; 2023; 22(10):909-919. PubMed ID: 37647330 [TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of immune checkpoint inhibitors: An updated review. Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168 [TBL] [Abstract][Full Text] [Related]
11. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171 [TBL] [Abstract][Full Text] [Related]
15. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. Chitsazan M; Amin A; Ladel L; Baig A; Chitsazan M Crit Pathw Cardiol; 2023 Sep; 22(3):69-82. PubMed ID: 37363862 [TBL] [Abstract][Full Text] [Related]